Brokerages Anticipate Editas Medicine Inc (NASDAQ:EDIT) Will Post Earnings of $0.04 Per Share

Wall Street analysts expect Editas Medicine Inc (NASDAQ:EDIT) to report earnings per share (EPS) of $0.04 for the current fiscal quarter, Zacks reports. Three analysts have provided estimates for Editas Medicine’s earnings, with the lowest EPS estimate coming in at ($0.89) and the highest estimate coming in at $0.69. Editas Medicine posted earnings per share of ($0.52) in the same quarter last year, which would indicate a positive year over year growth rate of 107.7%. The company is scheduled to report its next quarterly earnings results on Thursday, February 27th.

According to Zacks, analysts expect that Editas Medicine will report full year earnings of ($1.89) per share for the current year, with EPS estimates ranging from ($2.84) to ($1.25). For the next fiscal year, analysts anticipate that the firm will report earnings of ($2.99) per share, with EPS estimates ranging from ($3.34) to ($2.74). Zacks Investment Research’s EPS averages are a mean average based on a survey of sell-side research analysts that follow Editas Medicine.

Editas Medicine (NASDAQ:EDIT) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.66) EPS for the quarter, beating analysts’ consensus estimates of ($0.73) by $0.07. The company had revenue of $3.90 million for the quarter, compared to analyst estimates of $4.72 million. Editas Medicine had a negative return on equity of 56.53% and a negative net margin of 842.47%. The company’s quarterly revenue was down 73.1% compared to the same quarter last year. During the same period last year, the company earned ($0.32) earnings per share.

A number of analysts have issued reports on the company. ValuEngine raised Editas Medicine from a “hold” rating to a “buy” rating in a report on Wednesday, November 27th. Zacks Investment Research upgraded Editas Medicine from a “sell” rating to a “hold” rating and set a $25.00 price target for the company in a report on Thursday, November 14th. Morgan Stanley set a $29.00 price objective on Editas Medicine and gave the company a “hold” rating in a research report on Friday, August 9th. Finally, BidaskClub upgraded shares of Editas Medicine from a “strong sell” rating to a “sell” rating in a research note on Thursday, November 28th. One research analyst has rated the stock with a sell rating, four have given a hold rating and six have issued a buy rating to the company’s stock. Editas Medicine presently has a consensus rating of “Hold” and an average price target of $34.75.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Kavar Capital Partners LLC acquired a new position in shares of Editas Medicine during the 2nd quarter worth about $25,000. Capital Investment Advisory Services LLC acquired a new position in shares of Editas Medicine during the second quarter valued at about $25,000. Tower Research Capital LLC TRC acquired a new position in shares of Editas Medicine during the third quarter valued at about $25,000. Steward Partners Investment Advisory LLC bought a new stake in shares of Editas Medicine during the second quarter worth about $27,000. Finally, BSW Wealth Partners bought a new stake in shares of Editas Medicine during the second quarter worth about $28,000. Institutional investors and hedge funds own 86.14% of the company’s stock.

Shares of NASDAQ EDIT traded up $0.42 during trading hours on Thursday, hitting $30.32. 746,823 shares of the company’s stock were exchanged, compared to its average volume of 1,059,337. The company’s 50-day moving average price is $22.84 and its 200-day moving average price is $23.41. Editas Medicine has a 1-year low of $17.80 and a 1-year high of $32.46. The stock has a market capitalization of $1.55 billion, a price-to-earnings ratio of -13.01 and a beta of 2.64. The company has a debt-to-equity ratio of 0.06, a current ratio of 5.08 and a quick ratio of 5.08.

Editas Medicine Company Profile

Editas Medicine, Inc operates as a clinical stage genome editing company. The company focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary genome editing platform based on CRISPR technology to target genetically addressable diseases and therapeutic areas.

Featured Story: What is the Russell 2000 Index?

Get a free copy of the Zacks research report on Editas Medicine (EDIT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Editas Medicine (NASDAQ:EDIT)

Receive News & Ratings for Editas Medicine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Editas Medicine and related companies with MarketBeat.com's FREE daily email newsletter.